+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-17 Inhibitors for Psoriasis Market - Global Forecast 2025-2030- Product Image
IL-17 Inhibitors for Psoriasis Market - Global Forecast 2025-2030- Product Image
Sale

IL-17 Inhibitors for Psoriasis Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6117643
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

IL-17 inhibitors have rapidly advanced the treatment paradigm in psoriasis, offering targeted immunomodulation and improved clinical outcomes. As regulatory, economic, and technological factors reshape the competitive landscape, understanding the drivers and dynamics of this market is essential for senior decision-makers navigating innovation and investment strategies.

Market Snapshot: IL-17 Inhibitor Psoriasis Market

The IL-17 inhibitor psoriasis market is characterized by robust innovation and evolving treatment standards. The introduction of IL-17 inhibitors, including brodalumab, ixekizumab, and secukinumab, has shifted therapeutic expectations by focusing on key cytokine pathways. Pharmaceutical companies are leveraging breakthroughs in biotechnology, remote monitoring, and advanced drug delivery formats to improve adherence and deliver sustained skin clearance. Senior executives navigating this segment must remain agile, balancing regulatory updates, tariff impacts, and shifting payer models.

Scope & Segmentation

This comprehensive report provides in-depth coverage of the IL-17 inhibitor segment in psoriasis, exploring segmentation by product, indication, distribution, end user, therapeutic regimen, dosing frequency, and patient type, across multiple geographies:

  • Product: Brodalumab, Ixekizumab, Secukinumab
  • Indication: Plaque Psoriasis, Psoriatic Arthritis
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Chain Retail Pharmacies, Independent Retail Pharmacies
  • End User: Home Care Settings, Hospitals, Specialty Clinics
  • Therapeutic Regimen: Combination Therapy (including Cyclosporine, Methotrexate), Monotherapy
  • Dosing Frequency: Biweekly, Monthly
  • Patient Type: Adult, Pediatric (Adolescent, Child)
  • Regions: Americas (United States with state-level detail, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (multiple advanced and emerging markets), Asia-Pacific (major growth and healthcare investment hubs)
  • Key Companies: Novartis AG, Eli Lilly and Company, Bausch Health Companies Inc.

Key Takeaways for Senior Decision-Makers

  • IL-17 inhibitors have fundamentally shifted the psoriasis treatment landscape, achieving higher rates of efficacy and longer remission compared to prior therapies.
  • Increasing differentiation among products is evident, especially in how brodalumab, ixekizumab, and secukinumab are positioned according to their unique mechanisms, dosing, and onset profiles.
  • Regional adoption rates reflect differing healthcare infrastructures, with the Americas at the forefront, while Asia-Pacific sees rapid expansion from infrastructure investment and public awareness initiatives.
  • Collaboration between biotech innovators and established pharmaceutical manufacturers is accelerating the introduction of next-generation molecules and biosimilars to new and established markets.
  • Digital health platforms and telemedicine are improving patient monitoring and adherence, supporting the shift toward patient-centric, outcome-based care models.
  • Manufacturers respond to payer and provider demand for value-based reimbursement arrangements, while local production partnerships address supply stability and market access challenges.

Tariff Impact: Navigating Cost Pressures and Supply Resilience

The implementation of United States tariffs in 2025 has influenced the cost structure of IL-17 inhibitor therapies, compelling manufacturers to optimize global supply chains and explore local production agreements. Healthcare payers and providers have intensified value-focused negotiations, with procurement and distribution recalibrated to balance cost containment and patient access. This evolving tariff environment necessitates agile regulatory and commercial strategies to maintain market stability and growth.

Methodology & Data Sources

This report utilizes a multi-tiered research methodology, integrating primary interviews with dermatology and market access key opinion leaders, a thorough review of clinical trials and peer-reviewed literature, and comprehensive analysis of regulatory filings and proprietary databases. Data was triangulated across sources for accuracy, and analytical frameworks such as SWOT, Porter’s Five Forces, and scenario planning were deployed to contextualize market developments. Validation workshops with industry stakeholders ensured actionable, high-fidelity insights.

Why This Report Matters

  • Supports strategic decisions on investment, development, and commercialization within the growing IL-17 inhibitor psoriasis market.
  • Delivers critical clarity on tariff impacts, regional drivers, and segmentation opportunities to inform market entry and pricing strategies.
  • Enables executives to leverage emerging trends in digital health, value-based reimbursement, and collaboration models for sustainable growth.

Conclusion

The IL-17 inhibitor segment is shaping future standards in psoriasis care, blending targeted immunology with patient-focused delivery innovations. Strategic agility, data-driven planning, and partnership alignment will define success as the market continues to evolve and expand.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing integration of real-world evidence in demonstrating long term safety and efficacy of IL-17 inhibitors
5.2. Emergence of next generation IL-17 inhibitors with improved dosing convenience and more targeted biology
5.3. Growing payer restrictions and step therapy protocols shaping IL-17 inhibitor market access dynamics
5.4. Expansion of patient support programs and digital tools to enhance adherence to IL-17 inhibitor treatments
5.5. Intensifying competition from dual cytokine inhibitors and pipeline therapies challenging IL-17 dominance
5.6. Regional variations in IL-17 inhibitor uptake driven by differing reimbursement and healthcare infrastructure
5.7. Surge in head to head clinical trials comparing IL-17 inhibitors against alternative biologic classes
5.8. Rising investment in biomarker driven patient stratification to optimize IL-17 inhibitor therapy outcomes
5.9. Impact of COVID-19 on prescribing patterns and monitoring practices for IL-17 inhibitors in psoriasis patients
5.10. Increasing focus on long term safety data to support labeling expansion and market penetration for IL-17 inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. IL-17 Inhibitors for Psoriasis Market, by Product
8.1. Introduction
8.2. Brodalumab
8.3. Ixekizumab
8.4. Secukinumab
9. IL-17 Inhibitors for Psoriasis Market, by Indication
9.1. Introduction
9.2. Plaque Psoriasis
9.3. Psoriatic Arthritis
10. IL-17 Inhibitors for Psoriasis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.4.1. Chain
10.4.2. Independent
11. IL-17 Inhibitors for Psoriasis Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. IL-17 Inhibitors for Psoriasis Market, by Therapeutic Regimen
12.1. Introduction
12.2. Combination Therapy
12.2.1. Cyclosporine
12.2.2. Methotrexate
12.3. Monotherapy
13. IL-17 Inhibitors for Psoriasis Market, by Dosing Frequency
13.1. Introduction
13.2. Biweekly
13.3. Monthly
14. IL-17 Inhibitors for Psoriasis Market, by Patient Type
14.1. Introduction
14.2. Adult
14.3. Pediatric
14.3.1. Adolescent
14.3.2. Child
15. Americas IL-17 Inhibitors for Psoriasis Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa IL-17 Inhibitors for Psoriasis Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific IL-17 Inhibitors for Psoriasis Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Eli Lilly and Company
18.3.3. Bausch Health Companies Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. IL-17 INHIBITORS FOR PSORIASIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. IL-17 INHIBITORS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. IL-17 INHIBITORS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHAI
FIGURE 30. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHSTATISTICS
FIGURE 31. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHCONTACTS
FIGURE 32. IL-17 INHIBITORS FOR PSORIASIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IL-17 INHIBITORS FOR PSORIASIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 120. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 121. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 126. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 127. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 130. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 131. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 132. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 133. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 134. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 135. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 138. CANADA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 139. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 140. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 141. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 146. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 147. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 150. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 151. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 158. MEXICO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 241. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 242. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 243. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 248. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 249. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 252. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 253. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 254. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 255. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 256. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 257. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 260. GERMANY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 261. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 262. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 263. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 268. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 269. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 272. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 273. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 274. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 275. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 276. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 277. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 278. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 279. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 280. FRANCE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 301. ITALY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 302. ITALY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 303. ITALY IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 3

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this IL-17 Inhibitors for Psoriasis market report include:
  • Novartis AG
  • Eli Lilly and Company
  • Bausch Health Companies Inc.

Related Topics

Related Reports

Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2025-2030 - Product Image

Monoclonal Antibodies for Plaque Psoriasis Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Psoriasis Therapeutics Market - Global Forecast 2025-2030 - Product Image

Psoriasis Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Psoriasis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Psoriasis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 99 Pages
  • Global
From
Chronic Plaque Psoriasis Market Report 2025 - Product Image

Chronic Plaque Psoriasis Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Chronic Plaque Psoriasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 - Product Image

Chronic Plaque Psoriasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.